Related Experiment Video
Updated: Aug 9, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
The relationship between the acetylator and the sparteine hydroxylation polymorphisms
Journal of Medical Genetics
|April 1, 1986
Summary
This study found no significant difference in sparteine metabolism between rapid and slow acetylators. These findings suggest that acetylation phenotype does not impact the metabolic activity of sparteine hydroxylation in healthy individuals.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Human Physiology
Background:
- Individual differences in drug metabolism are influenced by genetic polymorphisms.
- Cytochrome P450 enzymes (e.g., CYP2D6) and N-acetyltransferases (e.g., NAT2) are key enzymes in drug metabolism.
- Phenotyping studies help elucidate the impact of genetic variations on drug metabolic pathways.
Purpose of the Study:
- To investigate the relationship between acetylation phenotype and sparteine hydroxylation metabolic activity.
- To determine if slow or rapid acetylator status affects the metabolic ratio of sparteine.
- To assess potential correlations between NAT2 and CYP2D6 activity in a healthy British Caucasian population.
Main Methods:
- Phenotyping of 38 healthy white British Caucasian subjects.
- Sparteine phenotyping to assess hydroxylator status (e.g., CYP2D6 activity).
- Sulphadimidine phenotyping to assess acetylator status (e.g., NAT2 activity).
Main Results:
- No significant difference was observed in the mean sparteine metabolic ratio.
- Comparison between rapid acetylator extensive hydroxylators (n=8) and slow acetylator extensive hydroxylators (n=27).
- The results indicate no statistical association between acetylation capacity and sparteine metabolic clearance.
Conclusions:
- Acetylation phenotype (NAT2 status) does not significantly influence the metabolic clearance of sparteine (CYP2D6 substrate).
- These findings suggest independent metabolic pathways for acetylation and sparteine hydroxylation in this cohort.
- Further research may explore other genetic or environmental factors influencing sparteine metabolism.
More Related Videos
Related Concept Videos
01:24Phase II Reactions: Acetylation Reactions
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...